Mark Yen, MD
PAREXEL Early Phase/California Clinical Trials Medical Group
2
2
2
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (2)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Paul Newell, MD
AstraZeneca
Shared therapeutic areas:
Worked with same sponsors:
emilie garrido pradalie
APHM
Shared therapeutic areas:
Waqar ahmed awan, Phd
Riphah International University
Shared therapeutic areas:
David Meeker, MD
Rhythm Pharmaceuticals, Inc.
Shared therapeutic areas:
Hagop Youssoufian, MD
Verastem, Inc.
Shared therapeutic areas:
Murad Alam, MD
Northwestern University
Shared therapeutic areas:
Ahmed Elshafeey, Ph.D. Pharma
Genuine Research Center
Shared therapeutic areas:
Suman Wason, MD
Lexicon Pharmaceuticals, Inc.
Shared therapeutic areas:
Suman Sheraz, PhD*
Riphah International University
Shared therapeutic areas:
Dorian Williams, M.D.
Kendle International Inc.
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (2)
Showing 2 of 2 trials
A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects
A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects
All 2 trials loaded